| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/BMJ.1.5644.614 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC1982429 |
| https://europepmc.org/articles/PMC1982429?pdf=render | ||
| https://syndication.highwire.org/content/doi/10.1136/bmj.1.5644.614 | ||
| P932 | PMC publication ID | 1982429 |
| P698 | PubMed publication ID | 4885615 |
| P5875 | ResearchGate publication ID | 18282307 |
| P2093 | author name string | G. Danta | |
| E. C. Hutchinson | |||
| J. Acheson | |||
| P2860 | cites work | Experimental and clinical observations on 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d) pyrimidine (Persantin) | Q79421850 |
| AUGMENTATION OF INTERCORONARY ANASTOMOSIS BY LONG-TERM ADMINISTRATION OF A VASODILATOR DRUG, DIPYRIDAMOLE (PERSANTIN) | Q42144064 | ||
| The effect of persantin on intercoronary collateral circulation and survival during gradual experimental coronary occlusion. A preliminary report. | Q42144859 | ||
| Effect of dipyridamole on human platelet behaviour. | Q54452376 | ||
| Effect of a Pyrimidopyrimidine Derivative on Thrombus Formation in the Rabbit | Q59096174 | ||
| Dipyridamole in the treatment of angina pectoris. A double-blind evaluation | Q71212204 | ||
| Reduction of Platelet Adhesiveness in Patients with Coronary Artery Disease | Q72046625 | ||
| Pharmacologic control of thromboembolic complications of cardiac-valve replacement. A preliminary report | Q72082794 | ||
| [Pharmacologically-induced development of coronary collaterals in relation to dosage] | Q72193213 | ||
| Enhancement of Coronary Vasodilator Action of Adenosine Triphosphate by Dipyridamole | Q72221006 | ||
| Evaluation of dipyridamole (Persantin) | Q76479653 | ||
| EXPERIMENTAL STUDIES ON THE EFFECTS OF PERSANTIN WITH NORMAL AND GO-DOGS | Q76828739 | ||
| PERSANTIN-- A DOUBLE BLIND STUDY | Q76854618 | ||
| LONG TERM DIPYRIDAMOLE THERAPY OF ANGINA PECTORIS | Q78537617 | ||
| The effect of Persantin on heart muscle sarcosomes | Q78977617 | ||
| A controlled clinical trial of 'persantin' (R A 8) in angina pectoris | Q79120118 | ||
| Controlled double-blind trial of "persantin" in treatment of angina pectoris | Q79237984 | ||
| [Function and energy metabolism of the exhausted heart muscle under the effects of 2,6-bis-(diethanolamino)-4,8-dipiperidino-pyrimido-(5,4-d)-pyrimidine.] | Q79418990 | ||
| P433 | issue | 5644 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | engineering | Q11023 |
| P1104 | number of pages | 2 | |
| P304 | page(s) | 614-615 | |
| P577 | publication date | 1969-03-01 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Controlled Trial of Dipyridamole in Cerebral Vascular Disease | |
| P478 | volume | 1 |
| Q34093604 | Aggrenox: a fixed-dose combination of aspirin and dipyridamole |
| Q70397672 | Anticoagulant and platelet-antiaggregating therapy in stroke and threatened stroke |
| Q66899646 | Antiplatelet Agents: A Review |
| Q28324307 | Antiplatelet Therapy in the Prevention of Stroke??? |
| Q39803954 | Antiplatelet drugs in thromboembolism |
| Q40595927 | Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis |
| Q39843044 | Antiplatelet drugs: clinical pharmacology and therapeutic use. |
| Q33660954 | Antiplatelet therapy for secondary stroke prevention |
| Q40599055 | Antithrombotic drugs: part II |
| Q38020361 | Antithrombotic treatment of cerebrovascular disease |
| Q40244546 | Brain hypoxia: the turning-point in the genesis of the migraine attack? |
| Q39766385 | Clinical evaluation and management of transient ischemic attacks. |
| Q28196865 | Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke |
| Q39853814 | Clinical pharmacology of inhibitors of platelet aggregation |
| Q39779330 | Coagulation for cardiologists |
| Q29619529 | Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration |
| Q40023249 | Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons |
| Q42401522 | Current areas of investigation on the medical management of stroke |
| Q33590385 | Current management of ischaemic stroke |
| Q36254840 | Diagnosis and prevention of atherosclerotic cerebral infarction. |
| Q24243858 | Dipyridamole for preventing stroke and other vascular events in patients with vascular disease |
| Q24246236 | Dipyridamole for preventing stroke and other vascular events in patients with vascular disease |
| Q41760001 | Do we still need dipyridamole? |
| Q66905017 | Drugs affecting platelet behaviour |
| Q93709266 | Effect of aspirin in amaurosis fugax |
| Q70119249 | Effect of dipyridamole on the incidence of clinically detectable deep-vein thrombosis |
| Q70444073 | Effects of Compound 48/80 on Platelets: Structural Alterations and Inhibition of Aggregation |
| Q70454233 | High-performance liquid chromatographic determination of dipyridamole |
| Q70714873 | Inhibition of the Function of Human Blood Platelets in vitro by VK 744 |
| Q43748461 | Lymphocyte stimulation by allogeneic cells in sperm-free ejaculates |
| Q33789869 | North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group |
| Q45271471 | Pharmacologic Control of Thromboembolic Complications of Cardiac-Valve Replacement |
| Q40809692 | Platelet aggregation inhibitors in neurology |
| Q39807700 | Platelet and fibrinogen kinetic evaluation of thrombogenesis |
| Q40173446 | Platelet inhibitors for TIAs. A review of prospective drug trial results |
| Q33990218 | Platelets, Thrombosis and Drugs |
| Q86527461 | Prevention of recurrent stroke in patients with systemic lupus erythematosus or lupus anticoagulant |
| Q71424482 | Prevention of stroke |
| Q28213134 | Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke |
| Q67542605 | Prophylaxis and therapy of shunt thrombosis in terminal renal insufficiency (author's transl) |
| Q28343787 | Rapid development of tolerance to dipyridamole-associated headaches |
| Q70378598 | Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration |
| Q46427553 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? |
| Q34052339 | Strokes, transient ischemic attacks and asymptomatic bruits |
| Q66700366 | Success or failure of dipyridamole in migraine |
| Q33870011 | THE PATHOGENESIS OF PULMONARY ARTERIOSCLEROSIS: PROPHYLAXIS WITH DRUGS WHICH AFFECT PLATELET AGGREGATION. |
| Q34462070 | The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke |
| Q69790035 | The Effect of RA 233 on Platelet Function in vitro and after Administration to Man |
| Q53680628 | The Effects of Acetylsalicylic Acid and Dipyridamole on Platelet Economy in Metastatic Cancer |
| Q39800664 | The role of platelets in thrombotic and vascular disease |
| Q86526304 | The strange story of aspirin and the prevention of stroke |
| Q39749150 | Thromboembolism and antithrombotic therapy in cerebrovascular disease |
| Q44843518 | Thromboembolism — A Continuing Challenge |
| Q30500131 | Transient cerebral ischemia |
| Q34101659 | Transient ischemic attacks and stroke. |
Search more.